69 related articles for article (PubMed ID: 10719810)
1. p53 protein expression and its prognostic importance in patients with nodal non-Hodgkin's lymphoma.
Ahn MJ; Kim H; Kim IS; Park JK; Ki MR; Park CK
J Korean Med Sci; 2000 Feb; 15(1):59-64. PubMed ID: 10719810
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications.
Jin YH; Park CK
J Korean Med Sci; 2002 Jun; 17(3):322-7. PubMed ID: 12068134
[TBL] [Abstract][Full Text] [Related]
4. [p53 mutation does not determine prognosis in non-Hodgkin's lymphoma].
Osada M; Ishioka C; Murakawa Y; Ichinohasama R; Kanamaru R; Ikawa S
Gan To Kagaku Ryoho; 1997 Feb; 24(4):471-5. PubMed ID: 9063486
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
[TBL] [Abstract][Full Text] [Related]
6. Expressions of p53 and PCNA do not correlate with the international index or early response to chemotherapy in non-Hodgkin's lymphoma.
Sakai A; Oda K; Asaoku H; Shintaku S; Hoshino S; Okita H; Kimura A
Am J Hematol; 1998 May; 58(1):42-8. PubMed ID: 9590148
[TBL] [Abstract][Full Text] [Related]
7. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of Livin expression in non-Hodgkin's lymphoma].
Gao JM; Wang X; Liu XQ; Ge XL; Ding M; Wang LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):385-90. PubMed ID: 20416174
[TBL] [Abstract][Full Text] [Related]
9. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma.
Osada M; Ishioka C; Ichinohasama R; Kadowaki I; Murakawa Y; Watanabe M; Kanamaru R; Ikawa S
Anticancer Drug Des; 1999 Apr; 14(2):107-14. PubMed ID: 10405637
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression.
Korkolopoulou P; Angelopoulou MK; Kontopidou F; Tsenga A; Patsouris E; Thomas-Tsagli E; Kittas C; Pangalis GA
Histopathology; 1998 Sep; 33(3):240-7. PubMed ID: 9777390
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
13. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas.
Doglioni C; Pelosio P; Mombello A; Scarpa A; Chilosi M
Hematol Pathol; 1991; 5(2):67-73. PubMed ID: 1680118
[TBL] [Abstract][Full Text] [Related]
15. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
16. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
Møller MB; Gerdes AM; Skjødt K; Mortensen LS; Pedersen NT
Clin Cancer Res; 1999 May; 5(5):1085-91. PubMed ID: 10353742
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.
Al-Moundhri MS; Nirmala V; Al-Hadabi I; Al-Mawaly K; Burney I; Al-Nabhani M; Thomas V; Ganguly SS; Grant C
J Surg Oncol; 2005 Sep; 91(4):243-52. PubMed ID: 16121348
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases.
Zarate-Osorno A; Medeiros LJ; Kingma DW; Longo DL; Jaffe ES
Am J Surg Pathol; 1993 Feb; 17(2):123-32. PubMed ID: 8422110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
